Key clinical point: Compared with 90% adherence, a 100% adherence to imatinib was associated with a 2-fold increase in achieving or maintaining treatment response in patients with chronic myeloid leukemia (CML), highlighting the urgent need to assess and promote patient adherence.
Major finding: A 90-day imatinib pill-count adherence of 100% vs. 90% increased the probabilities of achieving complete hematological response by 2.25-fold (probability of treatment response [pTR] 0.8416 vs. 0.3746), complete cytogenic response by 2.24-fold (pTR 0.8335 vs. 0.3714), major molecular response by 1.95-fold (pTR 0.7698 vs. 0.3938), and optimal response by 2.35-fold (pTR 0.8236 vs. 0.3512).
Study details: Findings are from a post hoc analysis of the ADAGIO study including 169 patients with CML.
Disclosures: This study did not receive any specific funding. Some investigators reported being equity shareholders and employees of or receiving honoraria from various sources including Novartis which funded the ADAGIO study.
Source: Obeng-Kusi M et al. Leuk Res. 2021;111:106734 (Oct 21). Doi: 10.1016/j.leukres.2021.106734.